Early Stage Pharmacological Validation of Novel Targets for Diseases of Interest to the NIDDK

This program provides funding to promote the early stage pharmacological validation of drug targets and accompanying small molecule chemical scaffolds in areas of interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDKK). NIDKK interest areas include obesity, liver disease, kidney disease, hematology, endocrinology, metabolism and cystic fibrosis.

Particular areas of research interest include, but are not limited to:

  • Using computational approaches to test chemical scaffolds
  • Generating pre-therapreutic protein for use in proof-of-concept studies
  • Developing novel formulations that can significantly enhance the therapeutic potential of the molecules being studied.
  • Protein engineering of prototype molecules

The open date for applications is January 5, 2013. For more information, see the link below:


Leave a Reply

Your email address will not be published. Required fields are marked *